Background-Hyperthyroidism increases heart rate, contractility, cardiac output, and metabolic rate. It is also accompanied by alterations in the regulation of cardiac substrate use. Specifically, hyperthyroidism increases the ex vivo activity of pyruvate dehydrogenase kinase, thereby inhibiting glucose oxidation via pyruvate dehydrogenase. Cardiac hypertrophy is another effect of hyperthyroidism, with an increase in the abundance of mitochondria. Although the hypertrophy is initially beneficial, it can eventually lead to heart failure. The aim of this study was to use hyperpolarized magnetic resonance spectroscopy to investigate the rate and regulation of in vivo pyruvate dehydrogenase flux in the hyperthyroid heart and to establish whether modulation of flux through pyruvate dehydrogenase would alter cardiac hypertrophy. Methods and Results-Hyperthyroidism was induced in 18 male Wistar rats with 7 daily intraperitoneal injections of freshly prepared triiodothyronine (0.2 mg ⅐ kg
T hyroid hormones regulate many aspects of growth, development, and energy metabolism, and are critical for normal cell function in multiple organs. [1] [2] [3] The heart is particularly sensitive to the action of thyroid hormones, with thyroid dysfunction having detrimental effects on the cardiovascular system. Minimal alterations in circulating thyroid hormone concentrations significantly alter many cardiac parameters. For instance, an increase in circulating thyroid hormone markedly increases heart rate, contractility, and cardiac output. 4 -7 Furthermore, hyperthyroid patients often develop hypertrophy, tachycardia, palpitations, fatigue, and atrial arrhythmias. 8 
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Hyperthyroidism is accompanied by alterations in the regulation of cardiac substrate use. Specifically, hyperthyroidism increases the ex vivo activity of pyruvate dehydrogenase kinase (PDK), 9, 10 thereby inhibiting glucose oxidation via pyruvate dehydrogenase (PDH). Pyruvate dehydrogenase catalyzes the conversion of pyruvate to acetyl-CoA, which can be used to generate adenosine triphosphate via the Krebs cycle. 11, 12 To date, it has not been possible to evaluate in vivo whether hyperthyroidism is associated with alterations in PDH flux and/or the mechanisms controlling in vivo PDH activity and regulation.
Magnetic resonance (MR) spectroscopy (MRS), in conjunction with 13 C-labeled substrates, has been used to study cardiac metabolism since the early 1980s; however, the inherently low sensitivity of this technique has largely limited its application to the study of steady-state metabolism in perfused hearts. The recent development of hyperpolarized MRS has addressed this problem by improving the signal-tonoise ratio Ͼ10 000-fold. 13 The increase in the signal-tonoise ratio has made it possible to visualize the uptake of 13 C-labeled metabolites in vivo and their metabolic conversion through specific enzymes in real time. 13, 14 The primary aim of this study was to use hyperpolarized 13 C-MRS to investigate the effects of hyperthyroidism on in vivo PDH flux after 7 days of chronically increased circulating thyroid hormone (triiodothyronine [T3]) concentrations. Metabolic perturbations were further defined with hyperpolarized [2- 13 C]pyruvate to assess Krebs cycle metabolism 15 and ex vivo metabolomics to evaluate differences in glycolytic substrate/product concentrations. 16, 17 A secondary aim was to use hyperpolarized 13 C-MRS to better characterize the mechanism of in vivo PDH regulation in the hyperthyroid heart. Two distinct mechanisms exist by which PDH flux can be regulated. The end products of fatty acid oxidation, acetyl-CoA and NADH, can directly inhibit PDH reducing PDH flux. 18, 19 Alternatively, acetyl-CoA and NADH can allosterically activate PDK, or in the longer term, transcriptional effectors may increase the specific activity and/or expression of PDK, thus increasing PDH phosphorylation and reducing PDH flux. 20 -22 To confirm whether any PDH inhibition observed in the hyperthyroid heart was PDK mediated, the PDK inhibitor dichloroacetic acid (DCA) was infused before MRS analysis. Dichloroacetic acid prevents PDK-mediated inhibition of PDH without affecting direct regulatory contributions from end-product inhibition on the PDH complex. 23 Therefore, by assessing the effect of DCA on PDH flux, we could confirm the involvement of PDK in the in vivo regulation of PDH.
Finally, to investigate the functional and metabolic consequences of PDH inhibition in the hyperthyroid heart, hyperpolarized MRS and cine MR imaging (MRI) were used to assess hyperthyroid animals with and without DCA treatment throughout the 7-day T3 administration period. In this way, the effects specifically resulting from PDH inhibition could be defined and the functional and metabolic consequences of alleviating PDH inhibition in the hyperthyroid heart could be evaluated.
Methods

Animal Preparation
The study conformed to the Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act of 1986 and to University of Oxford institutional guidelines. Eighteen male Wistar rats (weight, Ϸ250 g) were housed in a 12/12-hour light/dark cycle (lights on at 7 AM and off at 7 PM) in facilities at the University of Oxford. All animal studies were performed between 8 AM and 1 PM. Hyperthyroidism was induced with 7 daily intraperitoneal injections of freshly prepared triiodothyronine (T3; 0.2 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ) beginning on day 2 of the study.
At day 0 (before the first T3 injection to enable use as control data) and day 8, PDH flux was determined with hyperpolarized [1-13 C]pyruvate. 24 Krebs cycle metabolism was assessed on day 1 (also before the first T3 injection) and day 9 with hyperpolarized [2-13 C]pyruvate. 15 Hyperpolarized tracer (1 mL) was injected intravenously over 10 seconds into the anesthetized rat, and 60 individual cardiac spectra were acquired over 1 minute. Cardiac 13 C MR spectra were analyzed with the AMARES algorithm as implemented in the jMRUI software package. The rate of exchange of the 13 C label from the hyperpolarized pyruvate to each of its downstream metabolites was assessed with a kinetic model specifically designed to assess hyperpolarized pyruvate metabolism. 24, 25 The model accounts for many of the variables in the hyperpolarized experiment, including the rate of injection, the initial polarization level of the hyperpolarized pyruvate, and the rate of decay of each of the hyperpolarized compounds. The MRS acquisition and analysis protocol is described fully in the Methods section in the online-only Data Supplement.
Short-Term Dichloroacetic Acid Administration
One group of rats (nϭ6) received a 1-mL bolus of DCA via the tail vein (30 mg/mL in phosphate-buffered saline neutralized to pH 7.2 with concentrated NaOH), followed by a 0.5-mL infusion over 15 minutes immediately before infusion of hyperpolarized [1- 13 C]pyruvate on day 8.
Dichloroacetic Acid Treatment
One group of rats (nϭ5) were treated with DCA throughout the 7-day T3 administration period. Drinking water was replaced on day 2 (immediately after the first T3 injection) with water containing DCA (0.75 g/L neutralized to pH 7.2 with NaOH). Water intake was monitored daily.
Magnetic Resonance Imaging Measurements of Cardiac Function
On days 1 and 8, after hyperpolarized MRS analysis, cardiac function in animals without DCA infusion/treatment (nϭ7) and animals treated with DCA for 7 days (nϭ5) was assessed with MRI as described in the online-only Data Supplement. Briefly, cine MRIs, consisting of 28 to 35 frames per heart cycle, were acquired in Ϸ7 contiguous slices in the short-axis orientation covering the entire heart (field of view, 51.2ϫ51.2 mm; matrix size, 256ϫ256; slice thickness, 1.5 mm, giving a voxel size of 0.015 mm 3 ; echo time/repetition time, 1.43/4.6 milliseconds; gaussian radiofrequency excitation pulse, 0.5 milliseconds/17.5°, and averages, 4. End-diastolic (ED) and end-systolic (ES) frames were selected as those with the largest and smallest cavity volumes, respectively. Epicardial and endocardial borders were outlined with the freehand drawing function of ImageJ (National Institutes of Health, Bethesda, MD). Measurements from all slices were summed to calculate ED volume (EDV), ES volume (ESV), stroke volume (SVϭEDVϪESV), ejection fraction (EFϭSV/EDV), and cardiac output (COϭSVϫheart rate). Left ventricular mass was calculated as myocardial area times slice thickness times myocardial specific gravity (1.05). 26 
Plasma Metabolite Measurements
Immediately before examination with hyperpolarized pyruvate on days 0 and 8, Ϸ500 L of saphenous vein blood was sampled from anesthetized rats. All blood samples were immediately centrifuged (3400 rpm, 10 minutes, 4°C), and plasma was removed. A 50-L aliquot of plasma was separated, and 1 L tetrahydrolipstatin (30 g/mL) was added for nonesterified fatty acid analysis. All plasma samples were immediately frozen and stored at Ϫ80°C. An ABX Pentra 400 (Horiba ABX Diagnostics) was used to perform plasma assays for glucose, nonesterified fatty acids, triglycerides, lactate, cholesterol, and ␤-hydroxybutyrate. Rats were euthanized by exsan-guination after an overdose of isoflurane Ϸ50 minutes after MR analysis on day 9. Hearts were immediately excised, frozen in liquid nitrogen, and stored at Ϫ80°C for analysis of PDH activity and PDK4 protein expression.
Metabolomic Analysis of Cardiac Metabolites
Another group of rats were administered 7 daily T3 injections as described above (nϭ6) or received 7 daily intraperitoneal injections of saline water (0.2 mL) to serve as controls (nϭ6). On day 7, rats were euthanized by exsanguination after an overdose of isoflurane, and hearts were immediately excised, frozen in liquid nitrogen, and stored at Ϫ80°C. From control hearts, a section of tissue was taken for assessment of PDH activity and PDK4 protein expression. Metabolites were extracted from remaining heart tissue with methanol/chloroform/water and analyzed with 1 H-nuclear magnetic resonance spectroscopy as previously described. 16 Nuclear magnetic resonance spectra were processed with the ACD SpecManager 1D nuclear magnetic resonance processor (version 8; ACD, Toronto, Canada; see the online-only Data Supplement).
Pyruvate Dehydrogenase Activity Assay
The activity of the active and total fractions of PDH (PDH a and PDH t ) were determined spectrophotometrically by the method of Seymour and Chatham. 27 Briefly, the assay required the preparation of cardiac tissue with 1 of 2 homogenization buffers for either PDH a or PDH t measurement. We assessed PDH a when PDH was extracted under conditions in which both PDH phosphatase and PDK were inhibited by KH 2 PO 4 , potassium fluoride, DCA, and adenosine diphosphate. We assessed PDH t under conditions in which PDH phosphatase was stimulated by Mg 2ϩ and PDK was inhibited by DCA and adenosine diphosphate. The rate of NADH production over the first 30 seconds was used to determine activity (mol ⅐ min Ϫ1 ⅐ g Ϫ1 wet weight).
Western Blotting
Protein levels of PDK4 were measured in total left ventricular homogenates with SDS-PAGE and Western blotting. All samples were run in duplicate on separate gels to confirm results. Protein levels were related to internal standards to ensure homogeneity between samples and gels.
Statistical Analysis
Values are reported as meanϮSEM. Statistical significance between the control, T3, T3 plus short-term DCA administration, and T3 plus DCA treatment groups for the in vivo hyperpolarized data, in vitro metabolomics, PDH activity assay, plasma metabolite analysis, and Western blotting was assessed with a Kruskal-Wallis test followed by a Mann-Whitney test with a post hoc Bonferroni correction. 28 For the cine MRI data, the interaction between the effects of T3 and DCA was assessed with repeated measures ANOVA. Statistical significance between parameters measured on days 0 and 8 was assessed with a paired t test. Statistical significance between the T3 and T3 plus DCA treatment groups was assessed with a 2-sample t test assuming equal variances. Statistical significance was considered at PϽ0.05 level.
Results
Cardiac Metabolism in the Hyperthyroid Heart
Cardiac Pyruvate Dehydrogenase Flux Using hyperpolarized 13 C-MRS, we measured [1-13 C]pyruvate conversion into the metabolic product bicarbonate in real time ( Figure 1A ). The exchange of 13 C label from [1-
13 C]pyruvate into 13 C-bicarbonate gave a direct assessment of metabolic flux through PDH. 24 All data from day 0 were combined to form a single control data set. Before any T3 administration, the rate of label exchange from [1- 13 C]pyruvate to 13 C-bicarbonate in these animals was calculated to be 0.0055Ϯ0.0005 second Ϫ1 . After 7 days of T3 administration (T3 group), PDH flux was significantly reduced by 59% to 0.0022Ϯ0.0002 second Ϫ1 (Pϭ0.0003; Figure 1B ). The reduction in PDH a versus control PDH a was confirmed with an ex vivo spectrophotometric approach that detected a 46% decrease compared with control values (Pϭ0.0084; Figure 1C ).
Other Metabolic Abnormalities in the Hyperthyroid Heart [1-
13 C]alanine and [1-13 C]lactate appeared as a result of alanine aminotransferase-and lactate dehydrogenase-mediated 13 C-label exchange, respectively. The measured exchange rate of 13 C label from [1- 13 C]pyruvate to [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]alanine demonstrated a significant 62% increase in the T3 group relative to control animals (Pϭ0.0048; Figure 2A ). The rate of exchange of 13 C label into [1-13 C]lactate signal was also increased by 72% in hyperthyroid animals (Pϭ0.0049; Figure 2B ). Ex vivo 1 H-nuclear magnetic resonance spectroscopy analysis of the cardiac tissue from hyperthyroid hearts revealed that myocardial concentrations of glucose and glycogen were decreased to 73Ϯ7% (Pϭ0.0043) and 24Ϯ13% (Pϭ0.0087) of control values, respectively. The concentrations of the glycolytic products lactate and alanine were elevated to 137Ϯ14% (Pϭ0.026) and 162Ϯ21% (Pϭ0.0022) of the control values, respectively ( Figure 2C Table 1 ). This probably reflected a reduction in label reaching the Krebs cycle owing to the decrease in PDH flux. To try to account for this, values were further normalized against PDH flux values. After normalization, no significant difference was seen between the rates of 13 C-label incorporation into citrate, glutamate, or acetylcarnitine between the control and hyperthyroid animals.
Further evaluation of the data revealed a previously unobserved peak at Ϸ78.1 ppm, which was evident in the hyperthyroid heart spectra but barely quantifiable in the control spectra ( Figure 3A) . Further work enabled identification of this peak as [3- 13 C]citrate, which would be formed through anaplerotic processing of [2- 13 C]pyruvate via oxaloacetate. Because of the relatively low amplitude of the [3- 13 C]citrate peak, summing 10 seconds of data (from tϭ4 seconds) was necessary for quantification but revealed levels to be increased Ͼ4-fold in the T3 group relative to controls (Pϭ0.004; Figure 3B ).
Plasma Metabolites
After 7 days of T3 administration, there was a Ϸ3-fold increase in the concentration of circulating free fatty acids with levels of Ϸ2.1 mmol/L (Pϭ0.0008). The concentration of the ketone body ␤-hydroxybutyrate was significantly increased Ͼ4-fold in the hyperthyroid rats (Pϭ0.0003). No significant differences in plasma concentrations of cholesterol, lactate, or glucose were detected (Table 2) .
Pyruvate Dehydrogenase Regulation in the Hyperthyroid Heart
To study the predominant mechanism of PDH regulation in the hyperthyroid heart, hyperpolarized [1-
13 C]pyruvate me-tabolism was analyzed in hyperthyroid rats after the administration of DCA immediately before hyperpolarized MRS analysis. Infusion of DCA caused a 3.9-fold increase in PDH flux relative to flux in hyperthyroid hearts (Pϭ0.0012; Figure  1B ) and a 1.6-fold increase in PDH flux over control values (Pϭ0.0084). Figure 1D shows the expression of PDK4 protein as assessed by Western blotting (control, 1.0Ϯ0.3; T3, 1.5Ϯ0.3; Pϭ0.06).
Dichloroacetic Acid Treatment
To establish whether relieving the PDK-mediated inhibition of PDH would have any effect on the hyperthyroid heart, the functional and metabolic effects of DCA treatment throughout the 7-day T3 administration period were assessed. A combined hyperpolarized MRS and cine MRI approach was used. The results of this study are summarized in Figures 1  through 4 and Tables 1 through 3 . Dichloroacetic acid treatment increased PDH flux by 4.9-fold relative to levels in hyperthyroid animals (Pϭ0.0025) and by 2.0-fold relative to controls (Pϭ0.0017), which is similar in magnitude with the 1.6-fold increase observed in animals after a short-term DCA infusion. To verify these findings, a spectrophotometric assay was used to measure PDH activity (PDH a ) ex vivo. This confirmed that PDH a was increased 4.4-fold in DCA treated animals relative to T3 animals without DCA treatment (Pϭ0.0027; Figure 1C ). Figure 1D shows (Figure 2A ). Incorporation of 13 C label into [1-13 C]lactate was not statistically different from control levels or levels in untreated hyperthyroid animals ( Figure 2B ). Label incorporation into [1- C]acetylcarnitine at day 7 was significantly higher than in untreated hyperthyroid animals (PϽ0.01); however, when values were normalized to PDH flux to account for the increase in 13 C label entering the Krebs cycle, no significant differences were seen (Table 1 ). The amount of [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]citrate in treated animals at day 7 was Ͼ3-fold higher than control levels (Pϭ0.01; Figure 3B ). Analysis of circulating metabolite concentrations in plasma revealed increased ␤-hydroxybutyrate relative to control animals, whereas lactate, glucose, and cholesterol levels were decreased relative to controls (PϽ0.05). Dichloroacetic acid treatment also reduced circulating free fatty acid levels back to control levels ( Table 2 ). Left ventricular mass and the ratio of heart weight to body weight were significantly higher in all animals relative to day 0 (PϽ0.05; Table 3 ), indicating the development of hypertrophy in both untreated and DCA-treated animals. However, the average increase in LV mass was significantly lower in the treated hyperthyroid animals (100Ϯ20 mg) than in the untreated hyperthyroid animals (200Ϯ30 mg; Pϭ0.04; Figure 4 ). Cardiac output was increased in all animals compared with controls (PϽ0.05), but no significant difference was detected between treated and untreated animals ( Table 3 and Figure 4) . 
Discussion
In this study, we used hyperpolarized MRS to noninvasively measure the real-time conversion of [1-13 C]pyruvate to [ 13 C]bicarbonate to assess in vivo PDH flux in the hyperthyroid rat heart. We have, for the first time, demonstrated that cardiac PDH flux was decreased by 59% in vivo after 1 week of chronically elevated T3 levels. Reduced PDH flux would severely diminish the conversion of pyruvate to acetyl-CoA, thereby reducing the contribution of glucose oxidation to energy generation. The exact mechanism by which T3 reduces PDH flux is yet to be fully elucidated. Evidence suggests that T3 directly stimulates PDK4 gene expression via 2 thyroid response elements in the PDK4 promoter. 29 Conversely, other studies have shown that the reduction in PDH flux occurs after an increase in fatty acid oxidation. 30, 31 In support of the latter hypothesis, analysis of circulating plasma metabolite levels from rats administered T3 revealed an increase in the concentration of fatty acids and ␤-hydroxybutyrate relative to control levels. Our results are also consistent with the findings of Sugden et al, 32 who observed a decrease in the ratio of cardiac free to acylated carnitines, indicating increased myocardial fatty acid oxidation, and with many other studies that have demonstrated an increase in the circulating levels of fatty acids and their subsequent oxidation in hyperthyroidism. [33] [34] [35] The increase in circulating fatty acids is likely to be secondary to an increase in lipolysis in the white adipose tissue, which is known to be regulated in part by thyroid hormone. 36 We also found evidence of upregulation of several important energy-generating metabolic pathways. The ex vivo metabolomic experiments provided evidence of increased cardiac glucose use in rats treated with T3, despite the reduction in PDH flux. In line with this, increased [1- Figure 3 . A, Magnetic resonance (MR) cardiac spectrum of a triiodothyronine (T3) rat at day 8 after infusion of [2- 13 C]pyruvate. Ten individual spectra were summed to generate this spectrum (tϭ4 to 13 seconds). [2- 13 C]pyruvate and its metabolic products are annotated (unlabeled peaks are impurities in the [2- 13 C]pyruvate preparation). B, The [3-13 C]citrate/[2-13 C]pyruvate ratio in each group was assessed with hyperpolarized 13 C MR spectroscopy. Control indicates combined day 0 data (nϭ12); T3, hyperthyroid rats (nϭ7); T3ϩDCA Treatment, dichloroacetic acid (DCA) treatment throughout the 7-day T3 administration period (nϭ5). *PϽ0.05 vs control. A, Cardiac mass and B, cardiac function (cardiac output) assessed with magnetic resonance imaging in the hyperthyroid rat heart with and without dichloroacetic acid (DCA) treatment at day 0 (black) and day 8 (white) (*PϽ0.05). LV indicates left ventricular.
13 C]lactate and [1-13 C]alanine were detected in hyperthyroid hearts. In a previous study, nonoxidative glucose metabolism and glycogenolysis were observed to increase with hyperthyroidism. 37 The authors suggest that this was caused by a perturbation in energy metabolism, leading to increased levels of inorganic phosphate, which would stimulate glycogen metabolism.
We also found evidence of increased anaplerotic processing of pyruvate, a mechanism by which carbon flux into the Krebs cycle can be maintained under conditions of reduced PDH flux. We have been able to identify and quantify an MRS resonance corresponding to [3- 13 C]citrate, the formation of which has not previously been observed in vivo, in real time. Previous studies investigating substrate use in the hypertrophied heart have shown that reduced PDH flux is compensated for by an increase in pyruvate carboxylation via malic enzyme. 38 The expression of pyruvate carboxylase is also known to be increased by T3. 39 Therefore, it is plausible that in the hyperthyroid heart, pyruvate generated by increased glucose metabolism is metabolized anaplerotically to increase carbon flux into the Krebs cycle and to maintain energy generation under conditions of low PDH flux. The quantification in vivo of [3- 13 C]citrate in this study provided the first example of how hyperpolarized MRS can be used for the noninvasive assessment of anaplerosis, which will undoubtedly prove useful in future studies of cardiac disease.
Pyruvate Dehydrogenase Regulation
One interesting and potentially useful application of hyperpolarized MRS is probing mechanisms of metabolic regulation in vivo. For a number of reasons, existing in vitro and ex vivo analyses used for studying metabolic regulation are flawed, making translation of the acquired results into in vivo models problematic. For example, many assays fail to consider how metabolite composition in vivo may affect enzyme activity through processes such as substrate or end-product inhibition. These are of particular importance in studies of the effects of disorders known to perturb metabolism in vivo such as hyperthyroidism. By selectively modulating a known regulatory pathway and using hyperpolarized MRS to assess subsequent changes in metabolic flux, we can obtain novel information regarding metabolic regulation in disease. In this study, hyperthyroid rats were infused with the PDK inhibitor DCA immediately before analysis by hyperpolarized MRS. In these rats, the T3-mediated decrease in PDH flux was completely reversed. Because previous work has shown that DCA inhibits PDH in the presence of inhibitory concentrations of acetyl-CoA and NADH, 40 this result confirms that the observed reduction in PDH flux is mediated by PDK and that there is no discernable contribution from end-product inhibition. This supports the findings of Sugden et al 41 and Holness et al, 42 who observed an increase in PDK4 expression in hyperthyroid hearts. Although in our study the increase in PDK4 protein levels just failed to reach significance, this could be explained by the lower daily doses of T3 administered (0.2 versus 1.0 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ) or by the fact the hearts in our study were collected Ͼ24 hours after the final T3 injection.
Effects of Dichloroacetic Acid Treatment on the Hyperthyroid Heart
The hyperthyroid heart undergoes well-characterized functional and morphological changes in that heart rate, contractility, and cardiac output all increase and cardiac hypertrophy is frequently observed. To determine whether the inhibition of PDH, which results in the inability to use glucose efficiently as a substrate for adenosine triphosphate synthesis, is a contributing factor in the development of T3-mediated hypertrophy, we treated a group of hyperthyroid rats with DCA throughout the 7-day T3 administration period. Consistent with the role of DCA, we observed a significant increase in PDH flux, a reduction in circulating glucose levels, and a reduction in 13 C-label exchange with alanine, suggesting that the intracellular alanine pool size was reduced. Interestingly, despite the 4.9-fold increase in PDH flux with DCA treatment compared with untreated levels, no difference in PDK4 protein level was observed, confirming that long-term DCA administration affects only the activity, not the expression, of this enzyme. Further analysis of circulating metabolite levels revealed a normalization of circulating fatty acid concentrations and a reduction in glucose and cholesterol levels. These findings are consistent with a reduction in fatty acid oxidation, increased glucose oxidation, and decreased lipolysis in DCAtreated animals. Plasma lactate concentrations were also reduced, consistent with an increased level of lactate oxidation and a reduction in skeletal muscle glycolysis 43 after DCA administration. The levels of ␤-hydroxybutyrate, which were elevated in the T3 animals relative to controls, were further increased in the DCA-treated animals. This may be due to increased ketogenesis in the liver resulting from excess acetyl-CoA being generated from the significantly increased PDH flux, demonstrating the systemic effects that DCA treatment will have had on these animals.
Perhaps the most important alteration observed in the DCA-treated hearts was the 52% decrease in cardiac hypertrophy. In the hyperthyroid heart, increases in myocyte diameter and abundance of mitochondria are well established. 44 Such morphological changes allow increased energy generation via enhanced fatty acid oxidation, thus enabling the heart to meet the increase in workload. By allowing the hyperthyroid heart to use both fatty acids and carbohydrates as a fuel source, DCA treatment could increase mitochondrial flexibility, thereby reducing the requirement for increased abundance of mitochondria. Consistent with this, T3-mediated cardiac hypertrophy was reduced in animals treated with DCA. However, the hyperthyroid heart must still respond to the increase in workload and increase cardiac output to ensure efficient systemic O 2 delivery. This study therefore has demonstrated that by increasing the metabolic flexibility of the hyperthyroid heart, the response to increased levels of thyroid hormone is altered and cardiac hypertrophy is reduced. The side effects associated with DCA treatment, ie, pain, numbness, and peripheral neuropathy, 45, 46 prevent DCA from being a viable treatment for hyperthyroidism; however, our data suggest that alternative metabolic interventions may relieve some of the more serious symptoms associated with this disease and therefore warrant further investigation.
Limitations and Future Directions
The hyperpolarized [1- 13 C] and [2-13 C]pyruvate experiments described in this work produced spectra that were localized to the heart with a surface coil placed over the chest. It is certain that a small amount of contamination from neighboring organs, notably blood, liver, and skeletal muscle, made some contribution to the measured signals, especially in the detection of [1- 13 C]lactate and [1-13 C]alanine. However, we are confident that the appearance of metabolites downstream of PDH was dominated specifically by cardiac metabolism on the basis of both the metabolic time course of metabolite appearance and the high metabolic turnover of the heart. The time course of metabolite production closely followed the time course of injected pyruvate in that the initial detection and accumulation of bicarbonate, citrate, and acetylcarnitine occurred within 1 to 3 seconds of pyruvate arrival in the chest. It seems unlikely that metabolites produced anywhere outside the heart would appear so rapidly after cardiac pyruvate delivery. Furthermore, the extremely high rate of PDH and Krebs cycle flux in the heart 47 compared with liver 48, 49 and resting skeletal muscle 50, 51 provides further evidence that the bicarbonate measurements in this study reflected local cardiac metabolism.
The potential to study the metabolic effects of hyperthyroidism and other cardiovascular diseases in humans with the hyperpolarized techniques presented here is clear. The first trials in humans using hyperpolarized pyruvate as a metabolic biomarker are imminent and offer many advantages over other forms of metabolic assessment, ie, no radiation exposure and minimally invasive procedure. Metabolic studies using this technology can be integrated into existing MRI assessments of cardiac structure and function, as demonstrated here with a combined cine-MRI and hyperpolarized MRS assessment.
Summary
The visualization of real-time metabolism noninvasively has revealed for the first time that a significant PDK-mediated reduction in PDH flux in vivo contributes to the pathology of the hyperthyroid heart. This has been shown to be accompanied by increased glycolytic metabolism and anaplerotic flux into the Krebs cycle. Increasing the number of metabolic substrates available to the hyperthyroid heart significantly reduced hypertrophy while maintaining an elevated cardiac output. Future work will focus on alternative metabolic interventions that, like DCA, may alleviate the more serious effects of hyperthyroidism and slow progression of the cardiac effects of this disease.
